ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.
The final expert opinion on rotavirus vaccination in infancy aims to provide EU/EEA Member States with information to support the decision-making process on the possible introduction of rotavirus vaccination in infancy.
In Europe, routine rotavirus vaccination of infants at the national level has been introduced with one or two vaccine brands in Finland, Austria, Luxembourg and Belgium within well-baby clinics or administered by general practitioners and paediatricians. When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use.
When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use. To this end, ECDC has produced three generic protocols.
Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.
These article published in The Lancet provide new data for the efficacy of oral pentavalent rotavirus vaccine for prevention of severe rotavirus – related gastroenteritis in infant in developing countries